Pasireotide
Also referenced as: Signifor, Signifor LAR
A multireceptor somatostatin analogue used for selected endocrine excess syndromes.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved products treat selected adults with Cushing’s disease; Signifor LAR also treats selected adults with acromegaly. Formulation-specific criteria apply.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A multireceptor somatostatin analogue used for selected endocrine excess syndromes.
FDA-approved products treat selected adults with Cushing’s disease; Signifor LAR also treats selected adults with acromegaly. Formulation-specific criteria apply.
This is a hormone-suppressing medicine, not a growth-hormone enhancer. Product labels and eligibility differ.
Why It's Being Studied
- Cushing disease
- Acromegaly
- Somatostatin receptors
Mechanism of Action
Somatostatin-receptor activation, particularly at SSTR5, suppresses excess hormone signalling.
Somatostatin-receptor activation, particularly at SSTR5, suppresses excess hormone signalling. This is a hormone-suppressing medicine, not a growth-hormone enhancer. Product labels and eligibility differ.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Cushing disease
- Acromegaly
- Somatostatin receptors
- Subcutaneous approved medicine
- Approved depot formulation
Evidence Summary
Clinical studies support selected Cushing’s disease and acromegaly indications, depending on formulation and surgical context.
Higher tiers carry more weight. Filled tiers have evidence for Pasireotide; tap to read it.
- Clinical studies support selected Cushing’s disease and acromegaly indications, depending on formulation and surgical context.
2 cited sources.
- Prescribing label2
Human clinical evidence
- Clinical studies support selected Cushing’s disease and acromegaly indications, depending on formulation and surgical context.
Reported Adverse Events in Research
- Hyperglycemia or diabetes, hypocortisolism, gallstones, bradycardia and QT-related concerns require monitoring.
Limitations of Current Evidence
- This is a hormone-suppressing medicine, not a growth-hormone enhancer. Product labels and eligibility differ.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Pasireotide | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine, Approved depot formulation | Oral approved medicine |
| Cited sources | 2 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Pasireotide — prescribing label
- Prescribing label
SIGNIFOR LAR prescribing sources